Cargando…
P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
Autores principales: | Zhang, Jian, Song, Baoquan, Kong, Xin, Liu, Yin, Yang, Hanlin, Qiu, Huiying, Wu, Depei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429370/ http://dx.doi.org/10.1097/01.HS9.0000969212.99205.d9 |
Ejemplares similares
-
PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
por: Chen, Fangli, et al.
Publicado: (2023) -
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020) -
Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021) -
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021) -
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
por: Wang, Hongxia, et al.
Publicado: (2020)